Course for Brain Fatigue After Graves' Disease Controlled Study
NCT06134219 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2025-11-21
Summary
BACKGROUND. Mental fatigue (MF) is common in the most common form of hyperthyroidism, Graves' disease (GD). Clinically, MF is the primary mental symptom in patients with GD and is characterized by difficulties maintaining attention, exhaustion during cognitively demanding tasks, memory difficulties, irritability, and emotional lability. It may be the main contributing factor to the continued low quality of life in many patients with GD. MF can be measured with an MF score (MFS). The pathophysiology is unknown. There is no medical treatment, which requires patients to adapt to the situation.
AIM. In this project, the investigators want to test the hypothesis that mental fatigue improves - with secondary benefits on mental capacity, quality of life (QoL), and function - in patients with persistent mental fatigue in GD, through an MF course as an addition to standard care, compared to patients who receive only standard care. The investigators also test the hypothesis that the MF course is a cost-effective intervention.
METHOD. In a randomized controlled study, the investigators evaluate the effect of the MF course compared to standard care only in 96 patients with persistent MF in GD. Markers of mental health, QoL, and activity capacity are evaluated at baseline, 3, 6, and 12 months after intervention/inclusion. The primary outcome measure is MFS at 3 months.
CLINICAL SIGNIFICANCE. Patients report feeling neglected by healthcare for decades, and healthcare professionals are frustrated by the lack of guidance. Patient organizations highlight the need for research; they want mental symptoms to be characterized as a consequence of thyroid disease, they demand biomarkers, specific treatments, and personalized care. Our research group is working to address the cause of MF in GD and also to alleviate the symptoms. The MF course may prove to be an important tool that can be quickly implemented in clinical practice, especially in primary care. Our involvement in regional/national working groups will facilitate implementation in other units.
In this project, the investigators want to test the hypothesis that mental fatigue improves - with secondary benefits on mental capacity, quality of life (QoL), and function - in patients with persistent mental fatigue at GD, through an MF course as an addition to regular healthcare, compared to patients receiving only regular healthcare.
Conditions
- Graves Disease
Interventions
- OTHER
-
MF course
A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
- OTHER
-
Usual health care
The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
Sponsors & Collaborators
-
Vastra Gotaland Region
lead OTHER_GOV
Principal Investigators
-
Helena Filipsson Nyström · Sahlgrenska Universitet sjukhus
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 72 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-10
- Primary Completion
- 2026-07-10
- Completion
- 2027-05-10
Countries
- Sweden
Study Locations
More Related Trials
-
Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole
NCT02727738 ·Status: COMPLETED ·Phase: NA
-
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
NCT01039818 ·Status: COMPLETED ·Phase: PHASE3
-
Low-dose Radioiodine Ablation in Graves' Disease
NCT03110835 ·Status: COMPLETED
-
Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism
NCT02500342 ·Status: COMPLETED ·Phase: PHASE4
-
Block-replacement Therapy During Radioiodine Therapy
NCT00150124 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
NCT03009357 ·Status: COMPLETED
-
Heart Rate Monitoring by Wearable Devices in Graves' Disease
NCT04333342 ·Status: UNKNOWN ·Phase: NA
-
Register for Patients With Thyroid Hormone Resistance.
NCT06566066 ·Status: RECRUITING
-
Graves' Orbitopathy and Hypercholesterolemia
NCT02721992 ·Status: COMPLETED
-
Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone
NCT00917241 ·Status: COMPLETED ·Phase: PHASE4
-
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
NCT03066076 ·Status: UNKNOWN ·Phase: PHASE3
-
Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care
NCT06327828 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Antithyroid Drugs During Radioiodine Therapy
NCT00150137 ·Status: COMPLETED ·Phase: PHASE4
-
Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment
NCT01739972 ·Status: UNKNOWN ·Phase: NA
-
Cardiac Symptoms in Patients With Treated Graves' Disease
NCT06908369 ·Status: ACTIVE_NOT_RECRUITING
-
Subclinical Hypothyroidism and Mind in the Elderly
NCT00921050 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Shared Decision Making in Graves Disease - Graves Disease (GD) Choice
NCT02107794 ·Status: COMPLETED ·Phase: NA
-
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
NCT01295333 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease
NCT02339142 ·Status: UNKNOWN ·Phase: PHASE4
-
Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
NCT00388297 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Study of Different I-131 Doses in Graves' Disease
NCT02114619 ·Status: UNKNOWN ·Phase: NA
-
Intestinal Microbiota and Treatment of GD
NCT03433352 ·Status: UNKNOWN
-
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
NCT03098225 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Treatment of M.Graves With Radioactive Iodine: Follow-up Study
NCT00525122 ·Status: UNKNOWN
-
Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients
NCT01534169 ·Status: COMPLETED ·Phase: PHASE1